Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sen. Grassley Questions FDA’s Response To Acetaminophen Concerns

This article was originally published in The Tan Sheet

Executive Summary

Sen. Chuck Grassley, R-Iowa, asks FDA to account for its lag time in reacting to acetaminophen safety concerns in a March 20 letter to Commissioner Andrew von Eschenbach

You may also be interested in...

McNeil Sponsors “Answers In The Aisles” Web Site For OTC Analgesic Safety

McNeil Consumer Healthcare is launching a Web-based educational program to educate consumers on OTC medicine safety in the wake of an FDA proposed rule to implement stronger label warnings for nonprescription pain relievers

FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers

FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen

CHPA Campaign Asks Consumers To “CHEC” Their OTC Know-How

Results of a survey of OTC consumers revealing that one in six adults takes three or more pills at a single time were a driving factor behind CHPA's establishment of the Consumer Healthcare Education Center

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts